📊 ALLR Key Takeaways
Is Allarity Therapeutics, Inc. (ALLR) a Good Investment?
Allarity is a pre-commercial biotech company with minimal revenue ($25K) and substantial operating losses (-$2.8M net income) consuming cash at -$4.5M annually. While the company maintains adequate cash reserves ($19.8M) providing 4-5 years of operational runway and moderate leverage, the fundamental business model shows zero product commercialization and 100% dependency on successful drug development. Without demonstrated clinical progress or near-term revenue inflection, equity holders face severe dilution risk from future financing needs.
Allarity Therapeutics' fundamentals remain very weak: the company is generating negative revenue, deeply negative operating income, and substantial free cash outflows, which indicates the business is still far from a sustainable operating model. While the balance sheet is currently supported by a solid cash position and modest leverage, the ongoing cash burn materially outweighs those strengths and raises meaningful financing risk if commercialization or partnership progress does not improve.
Allarity Therapeutics, Inc. Key Strengths (ALLR)
- Adequate cash position of $19.8M providing material operational runway at current burn rate
- Moderate leverage with Debt/Equity ratio of 0.39x, reducing fixed obligations
- Positive current ratio of 1.23x indicates sufficient liquidity for near-term obligations
- Strong near-term liquidity with $16.89M in cash and a 2.33x current ratio
- Low balance-sheet leverage with debt-to-equity of 0.22x
- Net loss and diluted EPS improved year over year, indicating some loss compression
ALLR Stock Risks: Allarity Therapeutics, Inc. Investment Risks
- Near-zero revenue ($25K) with no visibility into commercialization timeline or product market fit
- Negative operating cash flow of -$4.5M annually with no path to breakeven demonstrated
- Severe execution risk typical of pre-commercial biotech; cash reserves deplete in 4-5 years without revenue growth or external financing
- Massive negative margins (-11000% net margin) indicating fundamental business model immaturity
- Negative revenue and severely negative margins point to very poor underlying business quality
- Operating cash flow of -$11.58M and free cash flow of -$11.88M imply a short cash runway without improvement
- Negative ROE, negative ROA, and deeply negative interest coverage show weak profitability and limited financial resilience
Key Metrics to Watch
- Quarterly cash burn rate trend and remaining runway timeline
- Clinical trial progression, regulatory milestones, and near-term approval catalysts
- Top-line revenue growth from any commercialized products
- Cash position and indicators of financing needs or capital raise announcements
- Quarterly operating cash burn relative to cash on hand
- Revenue normalization and operating loss trend
Allarity Therapeutics, Inc. (ALLR) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Allarity Therapeutics, Inc. presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.
ALLR Profit Margin, ROE & Profitability Analysis
ALLR vs Healthcare Sector: How Allarity Therapeutics, Inc. Compares
How Allarity Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Allarity Therapeutics, Inc. Stock Overvalued? ALLR Valuation Analysis 2026
Based on fundamental analysis, Allarity Therapeutics, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Allarity Therapeutics, Inc. Balance Sheet: ALLR Debt, Cash & Liquidity
ALLR Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Allarity Therapeutics, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-3,093.42 indicates the company is currently unprofitable.
ALLR Revenue Growth, EPS Growth & YoY Performance
ALLR Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | N/A | -$2.7M | $-0.17 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Allarity Therapeutics, Inc. Dividends, Buybacks & Capital Allocation
ALLR SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Allarity Therapeutics, Inc. (CIK: 0001860657)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ALLR
What is the AI rating for ALLR?
Allarity Therapeutics, Inc. (ALLR) has a Combined AI Grade of C from Claude (C) and ChatGPT (D) with 84% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are ALLR's key strengths?
Claude: Adequate cash position of $19.8M providing material operational runway at current burn rate. Moderate leverage with Debt/Equity ratio of 0.39x, reducing fixed obligations. ChatGPT: Strong near-term liquidity with $16.89M in cash and a 2.33x current ratio. Low balance-sheet leverage with debt-to-equity of 0.22x.
What are the risks of investing in ALLR?
Claude: Near-zero revenue ($25K) with no visibility into commercialization timeline or product market fit. Negative operating cash flow of -$4.5M annually with no path to breakeven demonstrated. ChatGPT: Negative revenue and severely negative margins point to very poor underlying business quality. Operating cash flow of -$11.58M and free cash flow of -$11.88M imply a short cash runway without improvement.
What is ALLR's revenue and growth?
Allarity Therapeutics, Inc. reported revenue of $25.0K.
Does ALLR pay dividends?
Allarity Therapeutics, Inc. pays dividends, with $0.3M distributed to shareholders in the trailing twelve months.
Where can I find ALLR SEC filings?
Official SEC filings for Allarity Therapeutics, Inc. (CIK: 0001860657) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ALLR's EPS?
Allarity Therapeutics, Inc. has a diluted EPS of $-0.73.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is ALLR's fundamental grade?
Based on our AI fundamental analysis in June 2026, Allarity Therapeutics, Inc. has a C grade with 84% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is ALLR stock overvalued or undervalued?
Valuation metrics for ALLR: ROE of -39.7% (sector avg: 15%), net margin of -11,000.0% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is ALLR's AI grade for 2026?
Our dual AI analysis gives Allarity Therapeutics, Inc. a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is ALLR's free cash flow?
Allarity Therapeutics, Inc.'s operating cash flow is $-4.5M, with capital expenditures of $64.0K. FCF margin is -18,228.0%.
How does ALLR compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -11,000.0% (avg: 12%), ROE -39.7% (avg: 15%), current ratio 1.23 (avg: 2).